GDC-0834_Racemate_COA_12298_MedChemExpress
橙皮苷对DOCA
网络出版时间：２０２３－０８－３０１４：３９：２０ 网络出版地址：ｈｔｔｐｓ：／／ｌｉｎｋ．ｃｎｋｉ．ｎｅｔ／ｕｒｌｉｄ／３４．１０８６．Ｒ．２０２３０８３０．１１５３．００２橙皮苷对ＤＯＣＡ／Ｓａｌｔ高血压大鼠心肾组织损害的保护作用杨 彬１，陈 哲２，全虹翰１，高海英１，朱 青１（１．广东药科大学中医药研究院，２．广州中医药大学科技创新中心，广东广州 ５１０００６）收稿日期：２０２３－０３－１０，修回日期：２０２３－０６－２０基金项目：国家自然科学基金资助项目（Ｎｏ８１７７０７０７）作者简介：杨 彬（１９９６－），女，硕士，研究方向：高血压及肾脏疾病的中医药防治，Ｅ ｍａｉｌ：ｙｏｕｎｇ９６１２＠１６３．ｃｏｍ；朱 青（１９８０－），男，博士，教授，硕士生导师，研究方向：高血压及肾脏药理学，通信作者，Ｅ ｍａｉｌ：ｚｙｑ９７３＠ｈｏｔｍａｉｌ．ｃｏｍｄｏｉ：１０．１２３６０／ＣＰＢ２０２２０８０４１文献标志码：Ａ文章编号：１００１－１９７８（２０２３）０９－１７０５－０６中国图书分类号：Ｒ ３３２；Ｒ２８４ １；Ｒ３２２ １１；Ｒ３２２ ６１；Ｒ３６４ ５；Ｒ５４４ １摘要：目的 探讨橙皮苷（ｈｅｓｐｅｒｉｄｉｎ，ＨＥＳ）对高血压大鼠心肾损害的保护作用及可能机制。
方法 雄性ＳＤ大鼠１８只随机分为３组：对照组（Ｃｔｒｌ）、高血压模型组（ＤＯＣＡ／Ｓａｌｔ）、橙皮苷给药组（ＤＯＣＡ／Ｓａｌｔ＋ＨＥＳ）。
ＨＥＳ持续给药４周，检测血压、血清肌酐、尿素氮等指标，ＨＥ、马松和天狼星红染色观察心、肾组织病理改变，Ｗｅｓｔｅｒｎｂｌｏｔ检测α ＳＭＡ、ｃｏｌｌａｇｅｎⅠ和ＴＧＦ β等蛋白表达，ｑＲＴ ＰＣＲ分别检测Ｎｌｒｐ３、ＴＮＦ α、ＩＬ １β、ＩＬ ６和ＮＯＸｓ的ｍＲＮＡ表达。
结果 与模型组比较，ＨＥＳ给药明显减缓ＤＯＣＡ／Ｓａｌｔ高血压的发生，改善高血压大鼠肾功能指标，减少肾脏和心脏组织纤维化，降低α ＳＭＡ、ｃｏｌｌａｇｅｎⅠ和ＴＧＦ β的表达，抑制Ｎｌｒｐ３，ＴＮＦ α、ＩＬ １β和ＩＬ ６等炎症因子释放，减少肾脏和心脏组织中ＮＯＸｓ表达。
SCItop区期刊表
刊名简称刊名全称ATMOS CHEM PHYS ATMOSPHERIC CHEMISTRY AND PHYSICSB AM METEOROL SOC BULLETIN OF THE AMERICAN METEOROLOGICAL SOCIETY CLIM DYNAM CLIMATE DYNAMICSCONTRIB MINERAL PETR CONTRIBUTIONS TO MINERALOGY AND PETROLOGY EARTH PLANET SC LETT EARTH AND PLANETARY SCIENCE LETTERSEARTH-SCI REV EARTH-SCIENCE REVIEWSGEOCHIM COSMOCHIM AC GEOCHIMICA ET COSMOCHIMICA ACTAGEOLOGY GEOLOGYGEOTEXT GEOMEMBRANES GEOTEXTILES AND GEOMEMBRANESJ CLIMATE JOURNAL OF CLIMATEJ PETROL JOURNAL OF PETROLOGYLIMNOL OCEANOGR LIMNOLOGY AND OCEANOGRAPHYNAT GEOSCI Nature GeosciencePALEOCEANOGRAPHY PALEOCEANOGRAPHYPRECAMBRIAN RES PRECAMBRIAN RESEARCHQUATERNARY SCI REV QUATERNARY SCIENCE REVIEWSREV GEOPHYS REVIEWS OF GEOPHYSICSGEOPHYS RES LETT GEOPHYSICAL RESEARCH LETTERSJ ATMOS SCI JOURNAL OF THE ATMOSPHERIC SCIENCESJ GEOPHYS RES JOURNAL OF GEOPHYSICAL RESEARCHJ HYDROL JOURNAL OF HYDROLOGYMON WEATHER REV MONTHLY WEATHER REVIEWANNU REV ASTRON ASTR ANNUAL REVIEW OF ASTRONOMY AND ASTROPHYSICS ASTRON ASTROPHYS REV ASTRONOMY AND ASTROPHYSICS REVIEWASTROPHYS J SUPPL S ASTROPHYSICAL JOURNAL SUPPLEMENT SERIES ASTROPHYS J ASTROPHYSICAL JOURNALACM COMPUT SURV ACM COMPUTING SURVEYSACM T GRAPHIC ACM TRANSACTIONS ON GRAPHICSACS NANO ACS NanoACTA BIOMATER Acta BiomaterialiaACTA MATER ACTA MATERIALIAADV APPL MECH ADVANCES IN APPLIED MECHANICSADV BIOCHEM ENG BIOT ADVANCES IN BIOCHEMICAL ENGINEERING / BIOTECHNOL ADV FUNCT MATER ADVANCED FUNCTIONAL MATERIALSADV MATER ADVANCED MATERIALSANNU REV BIOMED ENG ANNUAL REVIEW OF BIOMEDICAL ENGINEERINGANNU REV MATER RES ANNUAL REVIEW OF MATERIALS RESEARCHAPPL SPECTROSC REV APPLIED SPECTROSCOPY REVIEWSARTIF INTELL ARTIFICIAL INTELLIGENCEBIOMATERIALS BIOMATERIALSBIORESOURCE TECHNOL BIORESOURCE TECHNOLOGYBIOSENS BIOELECTRON BIOSENSORS & BIOELECTRONICSBIOTECHNOL ADV BIOTECHNOLOGY ADVANCESBIOTECHNOL BIOENG BIOTECHNOLOGY AND BIOENGINEERINGBIOTECHNOL BIOFUELS Biotechnology for BiofuelsCARBON CARBONCHEM MATER CHEMISTRY OF MATERIALSCOMPUT INTELL COMPUTATIONAL INTELLIGENCECRIT REV BIOTECHNOL CRITICAL REVIEWS IN BIOTECHNOLOGYCRIT REV FOOD SCI CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION CURR OPIN BIOTECH CURRENT OPINION IN BIOTECHNOLOGY ELECTROCHEM COMMUN ELECTROCHEMISTRY COMMUNICATIONSHUM-COMPUT INTERACT HUMAN-COMPUTER INTERACTIONIEEE J SEL AREA COMM IEEE JOURNAL ON SELECTED AREAS IN COMMUNICATIONS IEEE SIGNAL PROC MAG IEEE SIGNAL PROCESSING MAGAZINEIEEE T EVOLUT COMPUT IEEE TRANSACTIONS ON EVOLUTIONARY COMPUTATION IEEE T IND ELECTRON IEEE TRANSACTIONS ON INDUSTRIAL ELECTRONICS IEEE T NEURAL NETWOR IEEE TRANSACTIONS ON NEURAL NETWORKSIEEE T PATTERN ANAL IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHIN IEEE T SOFTWARE ENG IEEE TRANSACTIONS ON SOFTWARE ENGINEERINGINT J COMPUT VISION INTERNATIONAL JOURNAL OF COMPUTER VISIONINT J HYDROGEN ENERG INTERNATIONAL JOURNAL OF HYDROGEN ENERGYINT J NONLIN SCI NUM INTERNATIONAL JOURNAL OF NONLINEAR SCIENCES AND INT J PLASTICITY INTERNATIONAL JOURNAL OF PLASTICITYINT MATER REV INTERNATIONAL MATERIALS REVIEWSJ CATAL JOURNAL OF CATALYSISJ HAZARD MATER JOURNAL OF HAZARDOUS MATERIALSJ MATER CHEM JOURNAL OF MATERIALS CHEMISTRYJ MECH BEHAV BIOMED Journal of the Mechanical Behavior of Biomedical J NEURAL ENG Journal of Neural EngineeringJ POWER SOURCES JOURNAL OF POWER SOURCESJ WEB SEMANT Journal of Web SemanticsLAB CHIP LAB ON A CHIPMACROMOL RAPID COMM MACROMOLECULAR RAPID COMMUNICATIONS MACROMOLECULES MACROMOLECULESMAT SCI ENG R MATERIALS SCIENCE & ENGINEERING R-REPORTS MATER TODAY Materials TodayMED IMAGE ANAL MEDICAL IMAGE ANALYSISMETAB ENG METABOLIC ENGINEERINGMIS QUART MIS QUARTERLYMOL NUTR FOOD RES MOLECULAR NUTRITION & FOOD RESEARCHMRS BULL MRS BULLETINNANO LETT NANO LETTERSNANO TODAY Nano TodayNANOMED-NANOTECHNOL Nanomedicine-Nanotechnology Biology and Medicine NANOTECHNOLOGY NANOTECHNOLOGYNAT BIOTECHNOL NATURE BIOTECHNOLOGYNAT MATER NATURE MATERIALSNAT NANOTECHNOL Nature NanotechnologyORG ELECTRON ORGANIC ELECTRONICSP IEEE PROCEEDINGS OF THE IEEEPLASMONICS PlasmonicsPOLYM REV Polymer ReviewsPROG CRYST GROWTH CH PROGRESS IN CRYSTAL GROWTH AND CHARACTERIZATION PROG ENERG COMBUST PROGRESS IN ENERGY AND COMBUSTION SCIENCEPROG MATER SCI PROGRESS IN MATERIALS SCIENCEPROG PHOTOVOLTAICS PROGRESS IN PHOTOVOLTAICSPROG QUANT ELECTRON PROGRESS IN QUANTUM ELECTRONICSPROG SURF SCI PROGRESS IN SURFACE SCIENCERENEW SUST ENERG REV RENEWABLE & SUSTAINABLE ENERGY REVIEWSSMALL SMALLSOFT MATTER Soft MatterTRENDS BIOTECHNOL TRENDS IN BIOTECHNOLOGYTRENDS FOOD SCI TECH TRENDS IN FOOD SCIENCE & TECHNOLOGYVLDB J VLDB JOURNALAICHE J AICHE JOURNALAPPL MICROBIOL BIOT APPLIED MICROBIOLOGY AND BIOTECHNOLOGYCHEM ENG SCI CHEMICAL ENGINEERING SCIENCEELECTROCHIM ACTA ELECTROCHIMICA ACTAFOOD CHEM FOOD CHEMISTRYIEEE T ANTENN PROPAG IEEE TRANSACTIONS ON ANTENNAS AND PROPAGATION IEEE T AUTOMAT CONTR IEEE TRANSACTIONS ON AUTOMATIC CONTROLIEEE T INFORM THEORY IEEE TRANSACTIONS ON INFORMATION THEORYIEEE T MICROW THEORY IEEE TRANSACTIONS ON MICROWAVE THEORY AND TECHNI IEEE T SIGNAL PROCES IEEE TRANSACTIONS ON SIGNAL PROCESSINGIND ENG CHEM RES INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCHINT J HEAT MASS TRAN INTERNATIONAL JOURNAL OF HEAT AND MASS TRANSFER J AM CERAM SOC JOURNAL OF THE AMERICAN CERAMIC SOCIETYJ ELECTROCHEM SOC JOURNAL OF THE ELECTROCHEMICAL SOCIETYJ MEMBRANE SCI JOURNAL OF MEMBRANE SCIENCEMATER LETT MATERIALS LETTERSSCRIPTA MATER SCRIPTA MATERIALIASENSOR ACTUAT B-CHEM SENSORS AND ACTUATORS B-CHEMICALSURF COAT TECH SURFACE & COATINGS TECHNOLOGYSYNTHETIC MET SYNTHETIC METALSTHIN SOLID FILMS THIN SOLID FILMSJ OPER MANAG JOURNAL OF OPERATIONS MANAGEMENTMANAGE SCI MANAGEMENT SCIENCEOMEGA-INT J MANAGE S OMEGA-INTERNATIONAL JOURNAL OF MANAGEMENT SCIENC PROD OPER MANAG PRODUCTION AND OPERATIONS MANAGEMENTEUR J OPER RES EUROPEAN JOURNAL OF OPERATIONAL RESEARCH ACCOUNTS CHEM RES ACCOUNTS OF CHEMICAL RESEARCHACTA CRYSTALLOGR A ACTA CRYSTALLOGRAPHICA SECTION AALDRICHIM ACTA ALDRICHIMICA ACTAANGEW CHEM INT EDIT ANGEWANDTE CHEMIE-INTERNATIONAL EDITIONANNU REV PHYS CHEM ANNUAL REVIEW OF PHYSICAL CHEMISTRYCATAL REV CATALYSIS REVIEWS-SCIENCE AND ENGINEERINGCHEM REV CHEMICAL REVIEWSCHEM SOC REV CHEMICAL SOCIETY REVIEWSCOORDIN CHEM REV COORDINATION CHEMISTRY REVIEWSENERG ENVIRON SCI Energy & Environmental ScienceINT REV PHYS CHEM INTERNATIONAL REVIEWS IN PHYSICAL CHEMISTRYJ AM CHEM SOC JOURNAL OF THE AMERICAN CHEMICAL SOCIETYJ PHOTOCH PHOTOBIO C JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY C-PHO NAT PROD REP NATURAL PRODUCT REPORTSPROG POLYM SCI PROGRESS IN POLYMER SCIENCESURF SCI REP SURFACE SCIENCE REPORTSTRAC-TREND ANAL CHEM TRAC-TRENDS IN ANALYTICAL CHEMISTRYANAL CHEM ANALYTICAL CHEMISTRYJ ORG CHEM JOURNAL OF ORGANIC CHEMISTRYJ PHYS CHEM B JOURNAL OF PHYSICAL CHEMISTRY BLANGMUIR LANGMUIRAPPL CATAL B-ENVIRON APPLIED CATALYSIS B-ENVIRONMENTALB AM MUS NAT HIST BULLETIN OF THE AMERICAN MUSEUM OF NATURAL HISTO CRIT REV ENV SCI TEC CRITICAL REVIEWS IN ENVIRONMENTAL SCIENCE AND TE ECOL LETT ECOLOGY LETTERSECOL MONOGR ECOLOGICAL MONOGRAPHSECOLOGY ECOLOGYENVIRON HEALTH PERSP ENVIRONMENTAL HEALTH PERSPECTIVESENVIRON MICROBIOL ENVIRONMENTAL MICROBIOLOGYEVOLUTION EVOLUTIONFRONT ECOL ENVIRON FRONTIERS IN ECOLOGY AND THE ENVIRONMENT GLOBAL CHANGE BIOL GLOBAL CHANGE BIOLOGYGLOBAL ECOL BIOGEOGR GLOBAL ECOLOGY AND BIOGEOGRAPHYISME J ISME JournalATMOS ENVIRON ATMOSPHERIC ENVIRONMENTCHEMOSPHERE CHEMOSPHEREENVIRON SCI TECHNOL ENVIRONMENTAL SCIENCE & TECHNOLOGYWATER RES WATER RESEARCHADV AGRON ADVANCES IN AGRONOMYAGR FOREST METEOROL AGRICULTURAL AND FOREST METEOROLOGYATLA-ALTERN LAB ANIM ATLA-ALTERNATIVES TO LABORATORY ANIMALSEUR J SOIL SCI EUROPEAN JOURNAL OF SOIL SCIENCEFISH FISH FISH AND FISHERIESFISH OCEANOGR FISHERIES OCEANOGRAPHYFISH SHELLFISH IMMUN FISH & SHELLFISH IMMUNOLOGYFOOD BIOPROCESS TECH Food and Bioprocess TechnologyGEODERMA GEODERMAILAR J ILAR JOURNALJ AGR FOOD CHEM JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRYJ ANIM SCI JOURNAL OF ANIMAL SCIENCEJ DAIRY SCI JOURNAL OF DAIRY SCIENCEMOL BREEDING MOLECULAR BREEDINGREV FISH BIOL FISHER REVIEWS IN FISH BIOLOGY AND FISHERIESSOIL BIOL BIOCHEM SOIL BIOLOGY & BIOCHEMISTRYSOIL SCI SOC AM J SOIL SCIENCE SOCIETY OF AMERICA JOURNALTREE PHYSIOL TREE PHYSIOLOGYVET MICROBIOL VETERINARY MICROBIOLOGYVET RES VETERINARY RESEARCHAQUACULTURE AQUACULTURECAN J FISH AQUAT SCI CANADIAN JOURNAL OF FISHERIES AND AQUATIC SCIENC FOREST ECOL MANAG FOREST ECOLOGY AND MANAGEMENTJAVMA-J AM VET MED A JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL PLANT SOIL PLANT AND SOILAM J BIOETHICS AMERICAN JOURNAL OF BIOETHICSECONOMETRICA ECONOMETRICAJ ECONOMETRICS JOURNAL OF ECONOMETRICSAM J HUM GENET AMERICAN JOURNAL OF HUMAN GENETICSANNU REV BIOCHEM ANNUAL REVIEW OF BIOCHEMISTRYANNU REV BIOPH BIOM ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STR ANNU REV BIOPHYS Annual Review of BiophysicsANNU REV CELL DEV BI ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY ANNU REV ECOL EVOL S ANNUAL REVIEW OF ECOLOGY EVOLUTION AND SYSTEMATI ANNU REV ENTOMOL ANNUAL REVIEW OF ENTOMOLOGYANNU REV GENET ANNUAL REVIEW OF GENETICSANNU REV GENOM HUM G ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS ANNU REV MICROBIOL ANNUAL REVIEW OF MICROBIOLOGYANNU REV PHYTOPATHOL ANNUAL REVIEW OF PHYTOPATHOLOGYANNU REV PLANT BIOL ANNUAL REVIEW OF PLANT BIOLOGYCELL CELLCELL HOST MICROBE Cell Host & MicrobeCELL METAB Cell MetabolismCELL STEM CELL Cell Stem CellCRIT REV BIOCHEM MOL CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR B CURR BIOL CURRENT BIOLOGYCURR OPIN CELL BIOL CURRENT OPINION IN CELL BIOLOGYCURR OPIN GENET DEV CURRENT OPINION IN GENETICS & DEVELOPMENTCURR OPIN PLANT BIOL CURRENT OPINION IN PLANT BIOLOGYCURR OPIN STRUC BIOL CURRENT OPINION IN STRUCTURAL BIOLOGYDEV CELL DEVELOPMENTAL CELLGENE DEV GENES & DEVELOPMENTGENOME RES GENOME RESEARCHJ CELL BIOL JOURNAL OF CELL BIOLOGYMICROBIOL MOL BIOL R MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWSMOL CELL MOLECULAR CELLMOL SYST BIOL Molecular Systems BiologyNAT CELL BIOL NATURE CELL BIOLOGYNAT CHEM BIOL Nature Chemical BiologyNAT GENET NATURE GENETICSNAT METHODS NATURE METHODSNAT REV GENET NATURE REVIEWS GENETICSNAT REV MICROBIOL NATURE REVIEWS MICROBIOLOGYNAT REV MOL CELL BIO NATURE REVIEWS MOLECULAR CELL BIOLOGYNAT STRUCT MOL BIOL NATURE STRUCTURAL & MOLECULAR BIOLOGYPLANT CELL PLANT CELLPLOS BIOL PLOS BIOLOGYPLOS GENET PLoS GeneticsPLOS PATHOG PLoS PathogensPROG LIPID RES PROGRESS IN LIPID RESEARCHQ REV BIOPHYS QUARTERLY REVIEWS OF BIOPHYSICSTRENDS BIOCHEM SCI TRENDS IN BIOCHEMICAL SCIENCESTRENDS CELL BIOL TRENDS IN CELL BIOLOGYTRENDS ECOL EVOL TRENDS IN ECOLOGY & EVOLUTIONTRENDS GENET TRENDS IN GENETICSTRENDS PLANT SCI TRENDS IN PLANT SCIENCEAPPL ENVIRON MICROB APPLIED AND ENVIRONMENTAL MICROBIOLOGY BIOCHEM J BIOCHEMICAL JOURNALBIOPHYS J BIOPHYSICAL JOURNALDEVELOPMENT DEVELOPMENTEMBO J EMBO JOURNALJ BACTERIOL JOURNAL OF BACTERIOLOGYJ BIOL CHEM JOURNAL OF BIOLOGICAL CHEMISTRYJ MOL BIOL JOURNAL OF MOLECULAR BIOLOGYMOL CELL BIOL MOLECULAR AND CELLULAR BIOLOGYNUCLEIC ACIDS RES NUCLEIC ACIDS RESEARCHPLANT PHYSIOL PLANT PHYSIOLOGYACTA MATH-DJURSHOLM ACTA MATHEMATICAANN MATH ANNALS OF MATHEMATICSANN STAT ANNALS OF STATISTICSB AM MATH SOC BULLETIN OF THE AMERICAN MATHEMATICAL SOCIETY COMMUN PUR APPL MATH COMMUNICATIONS ON PURE AND APPLIED MATHEMATICS FOUND COMPUT MATH FOUNDATIONS OF COMPUTATIONAL MATHEMATICS INVENT MATH INVENTIONES MATHEMATICAEINVERSE PROBL INVERSE PROBLEMSJ AM MATH SOC JOURNAL OF THE AMERICAN MATHEMATICAL SOCIETYJ AM STAT ASSOC JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION J R STAT SOC B JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES MATH MOD METH APPL S MATHEMATICAL MODELS & METHODS IN APPLIED SCIENCE MATH PROGRAM MATHEMATICAL PROGRAMMINGMEM AM MATH SOC MEMOIRS OF THE AMERICAN MATHEMATICAL SOCIETY MULTISCALE MODEL SIM MULTISCALE MODELING & SIMULATIONMULTIVAR BEHAV RES MULTIVARIATE BEHAVIORAL RESEARCHNONLINEAR ANAL-REAL NONLINEAR ANALYSIS-REAL WORLD APPLICATIONSRISK ANAL RISK ANALYSISSIAM REV SIAM REVIEWSTAT SCI STATISTICAL SCIENCESTRUCT EQU MODELING STRUCTURAL EQUATION MODELING-A MULTIDISCIPLINARY FUZZY SET SYST FUZZY SETS AND SYSTEMSJ COMPUT APPL MATH JOURNAL OF COMPUTATIONAL AND APPLIED MATHEMATICS J DIFFER EQUATIONS JOURNAL OF DIFFERENTIAL EQUATIONSJ MATH ANAL APPL JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONNONLINEAR ANAL-THEOR NONLINEAR ANALYSIS-THEORY METHODS & APPLICATIONS SIAM J NUMER ANAL SIAM JOURNAL ON NUMERICAL ANALYSISSIAM J SCI COMPUT SIAM JOURNAL ON SCIENTIFIC COMPUTINGACTA CRYSTALLOGR A ACTA CRYSTALLOGRAPHICA SECTION AADV PHYS ADVANCES IN PHYSICSANNU REV FLUID MECH ANNUAL REVIEW OF FLUID MECHANICSANNU REV NUCL PART S ANNUAL REVIEW OF NUCLEAR AND PARTICLE SCIENCE CRIT REV SOLID STATE CRITICAL REVIEWS IN SOLID STATE AND MATERIALS SC J HIGH ENERGY PHYS JOURNAL OF HIGH ENERGY PHYSICSLASER PHOTONICS REV Laser & Photonics ReviewsLIVING REV RELATIV Living Reviews in RelativityMASS SPECTROM REV MASS SPECTROMETRY REVIEWSNAT PHOTONICS Nature PhotonicsNAT PHYS Nature PhysicsPHYS REP PHYSICS REPORTS-REVIEW SECTION OF PHYSICS LETTER PHYS REV LETT PHYSICAL REVIEW LETTERSPROG NUCL MAG RES SP PROGRESS IN NUCLEAR MAGNETIC RESONANCE SPECTROSC REP PROG PHYS REPORTS ON PROGRESS IN PHYSICSREV MOD PHYS REVIEWS OF MODERN PHYSICSAPPL PHYS LETT APPLIED PHYSICS LETTERSJ CHEM PHYS JOURNAL OF CHEMICAL PHYSICSPHYS REV B PHYSICAL REVIEW BPHYS REV D PHYSICAL REVIEW DADV DRUG DELIVER REV ADVANCED DRUG DELIVERY REVIEWSADV IMMUNOL ADVANCES IN IMMUNOLOGYAM J CLIN NUTR AMERICAN JOURNAL OF CLINICAL NUTRITIONAM J GASTROENTEROL AMERICAN JOURNAL OF GASTROENTEROLOGYAM J PSYCHIAT AMERICAN JOURNAL OF PSYCHIATRYAM J RESP CRIT CARE AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CAR AM J TRANSPLANT AMERICAN JOURNAL OF TRANSPLANTATIONANN INTERN MED ANNALS OF INTERNAL MEDICINEANN NEUROL ANNALS OF NEUROLOGYANN RHEUM DIS ANNALS OF THE RHEUMATIC DISEASESANN SURG ANNALS OF SURGERYANNU REV IMMUNOL ANNUAL REVIEW OF IMMUNOLOGYANNU REV MED ANNUAL REVIEW OF MEDICINEANNU REV NEUROSCI ANNUAL REVIEW OF NEUROSCIENCEANNU REV NUTR ANNUAL REVIEW OF NUTRITIONANNU REV PATHOL-MECH Annual Review of Pathology-Mechanisms of Disease ANNU REV PHARMACOL ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY ANNU REV PHYSIOL ANNUAL REVIEW OF PHYSIOLOGYANNU REV PSYCHOL ANNUAL REVIEW OF PSYCHOLOGYANNU REV PUBL HEALTH ANNUAL REVIEW OF PUBLIC HEALTHARCH GEN PSYCHIAT ARCHIVES OF GENERAL PSYCHIATRYARCH INTERN MED ARCHIVES OF INTERNAL MEDICINEARTERIOSCL THROM VAS ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY ARTHRITIS RHEUM-US ARTHRITIS AND RHEUMATISMBBA-REV CANCER BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER BEHAV BRAIN SCI BEHAVIORAL AND BRAIN SCIENCESBIOL PSYCHIAT BIOLOGICAL PSYCHIATRYBLOOD BLOODBLOOD REV BLOOD REVIEWSBRAIN BRAINBRAIN RES REV BRAIN RESEARCH REVIEWSBRIT MED J BRITISH MEDICAL JOURNALCA-CANCER J CLIN CA-A CANCER JOURNAL FOR CLINICIANSCAN MED ASSOC J CANADIAN MEDICAL ASSOCIATION JOURNALCANCER CELL CANCER CELLCANCER METAST REV CANCER AND METASTASIS REVIEWSCANCER RES CANCER RESEARCHCEREB CORTEX CEREBRAL CORTEXCIRC RES CIRCULATION RESEARCHCIRCULATION CIRCULATIONCLIN CANCER RES CLINICAL CANCER RESEARCHCLIN INFECT DIS CLINICAL INFECTIOUS DISEASESCLIN MICROBIOL REV CLINICAL MICROBIOLOGY REVIEWSCLIN PHARMACOL THER CLINICAL PHARMACOLOGY & THERAPEUTICSCRIT CARE MED CRITICAL CARE MEDICINECURR OPIN IMMUNOL CURRENT OPINION IN IMMUNOLOGYCURR OPIN LIPIDOL CURRENT OPINION IN LIPIDOLOGYCURR OPIN NEUROBIOL CURRENT OPINION IN NEUROBIOLOGYCURR OPIN PHARMACOL CURRENT OPINION IN PHARMACOLOGYDIABETES DIABETESDIABETES CARE DIABETES CAREDIABETOLOGIA DIABETOLOGIADRUG DISCOV TODAY DRUG DISCOVERY TODAYDRUG RESIST UPDATE DRUG RESISTANCE UPDATESEMERG INFECT DIS EMERGING INFECTIOUS DISEASESENDOCR REV ENDOCRINE REVIEWSEPIDEMIOL REV EPIDEMIOLOGIC REVIEWSEUR HEART J EUROPEAN HEART JOURNALEUR UROL EUROPEAN UROLOGYFRONT NEUROENDOCRIN FRONTIERS IN NEUROENDOCRINOLOGY GASTROENTEROLOGY GASTROENTEROLOGYGASTROINTEST ENDOSC GASTROINTESTINAL ENDOSCOPYGUT GUTHEPATOLOGY HEPATOLOGYHUM MUTAT HUMAN MUTATIONHUM REPROD UPDATE HUMAN REPRODUCTION UPDATEHYPERTENSION HYPERTENSIONIMMUNITY IMMUNITYIMMUNOL REV IMMUNOLOGICAL REVIEWSJ ALLERGY CLIN IMMUN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGYJ AM COLL CARDIOL JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGYJ AM SOC NEPHROL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGYJ AUTOIMMUN JOURNAL OF AUTOIMMUNITYJ BONE MINER RES JOURNAL OF BONE AND MINERAL RESEARCHJ CLIN INVEST JOURNAL OF CLINICAL INVESTIGATIONJ CLIN ONCOL JOURNAL OF CLINICAL ONCOLOGYJ EXP MED JOURNAL OF EXPERIMENTAL MEDICINEJ HEPATOL JOURNAL OF HEPATOLOGYJ NATL CANCER I JOURNAL OF THE NATIONAL CANCER INSTITUTEJ NEUROSCI JOURNAL OF NEUROSCIENCEJ NUCL MED JOURNAL OF NUCLEAR MEDICINEJAMA-J AM MED ASSOC JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LANCET LANCETLANCET INFECT DIS LANCET INFECTIOUS DISEASESLANCET NEUROL LANCET NEUROLOGYLANCET ONCOL LANCET ONCOLOGYLEUKEMIA LEUKEMIAMED RES REV MEDICINAL RESEARCH REVIEWSMOL ASPECTS MED MOLECULAR ASPECTS OF MEDICINEMOL PSYCHIATR MOLECULAR PSYCHIATRYNAT CLIN PRACT ONCOL Nature Clinical Practice OncologyNAT IMMUNOL NATURE IMMUNOLOGYNAT MED NATURE MEDICINENAT NEUROSCI NATURE NEUROSCIENCENAT REV CANCER NATURE REVIEWS CANCERNAT REV DRUG DISCOV NATURE REVIEWS DRUG DISCOVERYNAT REV IMMUNOL NATURE REVIEWS IMMUNOLOGYNAT REV NEUROSCI NATURE REVIEWS NEUROSCIENCENEUROLOGY NEUROLOGYNEURON NEURONNEUROPSYCHOPHARMACOL NEUROPSYCHOPHARMACOLOGYNEUROSCI BIOBEHAV R NEUROSCIENCE AND BIOBEHAVIORAL REVIEWSNEW ENGL J MED NEW ENGLAND JOURNAL OF MEDICINEOBES REV Obesity ReviewsONCOGENE ONCOGENEPHARMACOL REV PHARMACOLOGICAL REVIEWSPHARMACOL THERAPEUT PHARMACOLOGY & THERAPEUTICSPHYSIOL REV PHYSIOLOGICAL REVIEWSPHYSIOLOGY PHYSIOLOGYPLOS MED PLOS MEDICINEPROG NEUROBIOL PROGRESS IN NEUROBIOLOGYPROG RETIN EYE RES PROGRESS IN RETINAL AND EYE RESEARCHPSYCHOL BULL PSYCHOLOGICAL BULLETINPSYCHOL REV PSYCHOLOGICAL REVIEWREV MED VIROL REVIEWS IN MEDICAL VIROLOGYSCHIZOPHRENIA BULL SCHIZOPHRENIA BULLETINSEMIN CANCER BIOL SEMINARS IN CANCER BIOLOGYSEMIN IMMUNOL SEMINARS IN IMMUNOLOGYSTEM CELLS STEM CELLSSTROKE STROKETHORAX THORAXTRENDS COGN SCI TRENDS IN COGNITIVE SCIENCESTRENDS ENDOCRIN MET TRENDS IN ENDOCRINOLOGY AND METABOLISMTRENDS IMMUNOL TRENDS IN IMMUNOLOGYTRENDS MOL MED TRENDS IN MOLECULAR MEDICINETRENDS NEUROSCI TRENDS IN NEUROSCIENCESTRENDS PHARMACOL SCI TRENDS IN PHARMACOLOGICAL SCIENCESWHO TECH REP SER WHO TECHNICAL REPORT SERIESAM J CARDIOL AMERICAN JOURNAL OF CARDIOLOGYAM J EPIDEMIOL AMERICAN JOURNAL OF EPIDEMIOLOGYAM J PATHOL AMERICAN JOURNAL OF PATHOLOGYAM J PHYSIOL-HEART C AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULA ANTIMICROB AGENTS CH ANTIMICROBIAL AGENTS AND CHEMOTHERAPYBRIT J CANCER BRITISH JOURNAL OF CANCERCANCER-AM CANCER SOC CANCERCHEST CHESTCNS NEUROL DISORD-DR CNS & Neurological Disorders-Drug Targets ENDOCRINOLOGY ENDOCRINOLOGYEUR J NEUROSCI EUROPEAN JOURNAL OF NEUROSCIENCEFREE RADICAL BIO MED FREE RADICAL BIOLOGY AND MEDICINEINFECT IMMUN INFECTION AND IMMUNITYINT J CANCER INTERNATIONAL JOURNAL OF CANCERINT J RADIAT ONCOL INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOL INVEST OPHTH VIS SCI INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCEJ APPL PHYSIOL JOURNAL OF APPLIED PHYSIOLOGYJ CLIN ENDOCR METAB JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM J CLIN MICROBIOL JOURNAL OF CLINICAL MICROBIOLOGYJ COMP NEUROL JOURNAL OF COMPARATIVE NEUROLOGYJ IMMUNOL JOURNAL OF IMMUNOLOGYJ INFECT DIS JOURNAL OF INFECTIOUS DISEASESJ MED CHEM JOURNAL OF MEDICINAL CHEMISTRYJ NEUROCHEM JOURNAL OF NEUROCHEMISTRYJ NEUROPHYSIOL JOURNAL OF NEUROPHYSIOLOGYJ NUTR JOURNAL OF NUTRITIONJ PHARMACOL EXP THER JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPE J PHYSIOL-LONDON JOURNAL OF PHYSIOLOGY-LONDONJ UROLOGY JOURNAL OF UROLOGYJ VIROL JOURNAL OF VIROLOGYKIDNEY INT KIDNEY INTERNATIONALNEUROIMAGE NEUROIMAGENEUROSCIENCE NEUROSCIENCEPEDIATRICS PEDIATRICSRADIOLOGY RADIOLOGYTRANSPLANTATION TRANSPLANTATIONVIROLOGY VIROLOGYNATURE NATUREP NATL ACAD SCI USA PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES SCIENCE SCIENCEANN NY ACAD SCI ANNALS OF THE NEW YORK ACADEMY OF SCIENCESISSN大类名称复分大类分区是否top期刊2009年影响因子1680-7316地学1Y 4.881 0003-0007地学1Y 6.123 0930-7575地学1Y 3.917 0010-7999地学1Y 3.497 0012-821X地学1Y 4.062 0012-8252地学1Y 6.942 0016-7037地学1Y 4.385 0091-7613地学1Y 4.368 0266-1144地学1Y 4.039 0894-8755地学1Y 3.363 0022-3530地学1Y 3.738 0024-3590地学1Y 3.545 1752-0894地学1Y8.108 0883-8305地学1Y 3.644 0301-9268地学1Y 3.574 0277-3791地学1Y 4.245 8755-1209地学1Y8.021 0094-8276地学2Y 3.204 0022-4928地学2Y 2.911 0148-0227地学2Y 3.082 0022-1694地学2Y 2.433 0027-0644地学2Y 2.238 0066-4146地学天文1Y25.640 0935-4956地学天文1Y11.857 0067-0049地学天文1Y12.771 0004-637X地学天文2Y7.364 0360-0300工程技术1Y7.667 0730-0301工程技术1Y 3.619 1936-0851工程技术1Y7.493 1742-7061工程技术1Y 3.975 1359-6454工程技术1Y 3.760 0065-2156工程技术1Y 5.500 0724-6145工程技术1Y 4.165 1616-301X工程技术1Y 6.990 0935-9648工程技术1Y8.379 1523-9829工程技术1Y11.235 1531-7331工程技术1Y7.911 0570-4928工程技术1Y 3.243 0004-3702工程技术1Y 3.036 0142-9612工程技术1Y7.365 0960-8524工程技术1Y 4.253 0956-5663工程技术1Y 5.429 0734-9750工程技术1Y8.250 0006-3592工程技术1Y 3.377 1754-6834工程技术1Y 4.118 0008-6223工程技术1Y 4.5040897-4756工程技术1Y 5.368 0824-7935工程技术1Y 5.378 0738-8551工程技术1Y 3.567 1040-8398工程技术1Y 3.725 0958-1669工程技术1Y7.820 1388-2481工程技术1Y 4.243 0737-0024工程技术1Y 6.190 0733-8716工程技术1Y 3.758 1053-5888工程技术1Y 4.914 1089-778X工程技术1Y 4.589 0278-0046工程技术1Y 4.678 1045-9227工程技术1Y 2.889 0162-8828工程技术1Y 4.378 0098-5589工程技术1Y 3.750 0920-5691工程技术1Y 3.508 0360-3199工程技术1Y 3.945 1565-1339工程技术1Y 5.276 0749-6419工程技术1Y 4.791 0950-6608工程技术1Y 4.857 0021-9517工程技术1Y 5.288 0304-3894工程技术1Y 4.144 0959-9428工程技术1Y 4.795 1751-6161工程技术1Y 3.176 1741-2560工程技术1Y 3.739 0378-7753工程技术1Y 3.792 1570-8268工程技术1Y 3.412 1473-0197工程技术1Y 6.306 1022-1336工程技术1Y 4.263 0024-9297工程技术1Y 4.539 0927-796X工程技术1Y12.217 1369-7021工程技术1Y11.452 1361-8415工程技术1Y 3.093 1096-7176工程技术1Y 4.725 0276-7783工程技术1Y 4.485 1613-4125工程技术1Y 4.356 0883-7694工程技术1Y 6.330 1530-6984工程技术1Y9.991 1748-0132工程技术1Y13.237 1549-9634工程技术1Y 5.440 0957-4484工程技术1Y 3.137 1087-0156工程技术1Y29.495 1476-1122工程技术1Y29.504 1748-3387工程技术1Y26.309 1566-1199工程技术1Y 3.262 0018-9219工程技术1Y 4.878 1557-1955工程技术1Y 3.723 1558-3724工程技术1Y 5.6120960-8974工程技术1Y9.250 0360-1285工程技术1Y11.024 0079-6425工程技术1Y15.769 1062-7995工程技术1Y 4.702 0079-6727工程技术1Y 4.091 0079-6816工程技术1Y7.913 1364-0321工程技术1Y 4.842 1613-6810工程技术1Y 6.171 1744-683X工程技术1Y 4.869 0167-7799工程技术1Y 6.909 0924-2244工程技术1Y 4.051 1066-8888工程技术1Y 4.517 0001-1541工程技术2Y 1.955 0175-7598工程技术2Y 2.896 0009-2509工程技术2Y 2.136 0013-4686工程技术2Y 3.325 0308-8146工程技术2Y 3.146 0018-926X工程技术2Y 2.011 0018-9286工程技术2Y 2.556 0018-9448工程技术2Y 2.357 0018-9480工程技术2Y 2.076 1053-587X工程技术2Y 2.212 0888-5885工程技术2Y 1.758 0017-9310工程技术2Y 1.947 0002-7820工程技术2Y 1.944 0013-4651工程技术2Y 2.241 0376-7388工程技术2Y 3.203 0167-577X工程技术2Y 1.940 1359-6462工程技术2Y 2.949 0925-4005工程技术2Y 3.083 0257-8972工程技术2Y 1.793 0379-6779工程技术2Y 1.901 0040-6090工程技术2Y 1.727 0272-6963管理科学1Y 3.238 0025-1909管理科学1Y 2.227 0305-0483管理科学1Y 3.101 1059-1478管理科学1Y 2.080 0377-2217管理科学2Y 2.093 0001-4842化学1Y18.203 0108-7673化学化学－晶体1Y49.926 0002-5100化学1Y18.688 1433-7851化学1Y11.829 0066-426X化学1Y17.464 0161-4940化学1Y7.765 0009-2665化学1Y35.957 0306-0012化学1Y20.086 0010-8545化学1Y11.2251754-5692化学1Y8.500 0144-235X化学1Y 5.000 0002-7863化学1Y8.580 1389-5567化学1Y7.952 0265-0568化学1Y9.202 0079-6700化学1Y23.753 0167-5729化学1Y13.462 0165-9936化学1Y 6.546 0003-2700化学2Y 5.214 0022-3263化学2Y 4.219 1520-6106化学2Y 3.471 0743-7463化学2Y 3.898 0926-3373环境科学1Y 5.252 0003-0090环境科学1Y 4.133 1064-3389环境科学1Y7.091 1461-023X环境科学1Y10.318 0012-9615环境科学1Y 4.862 0012-9658环境科学1Y 4.411 0091-6765环境科学1Y 6.191 1462-2912环境科学1Y 4.909 0014-3820环境科学1Y 5.429 1540-9295环境科学1Y 6.922 1354-1013环境科学1Y 5.561 1466-822X环境科学1Y 5.913 1751-7362环境科学1Y 6.397 1352-2310环境科学2Y 3.139 0045-6535环境科学2Y 3.253 0013-936X环境科学2Y 4.630 0043-1354环境科学2Y 4.355 0065-2113农林科学1Y 3.800 0168-1923农林科学1Y 3.197 0261-1929农林科学1Y 1.580 1351-0754农林科学1Y 2.131 1467-2960农林科学1Y 4.489 1054-6006农林科学1Y 2.427 1050-4648农林科学1Y 2.892 1935-5130农林科学1Y 2.238 0016-7061农林科学1Y 2.461 1084-2020农林科学1Y 2.806 0021-8561农林科学1Y 2.469 0021-8812农林科学1Y 2.466 0022-0302农林科学1Y 2.463 1380-3743农林科学1Y 2.272 0960-3166农林科学1Y 2.161 0038-0717农林科学1Y 2.978 0361-5995农林科学1Y 2.179 0829-318X农林科学1Y 2.2920378-1135农林科学1Y 2.874 0928-4249农林科学1Y 3.579 0044-8486农林科学2Y 1.925 0706-652X农林科学2Y 1.951 0378-1127农林科学2Y 1.950 0003-1488农林科学2Y 1.714 0032-079X农林科学2Y 2.517 1526-5161社会科学1Y 4.000 0012-9682社会科学1Y 4.000 0304-4076社会科学2Y 1.902 0002-9297生物1Y12.303 0066-4154生物1Y29.875 1056-8700生物1Y18.955 1936-122X生物1Y19.304 1081-0706生物1Y19.571 1543-592X生物1Y8.190 0066-4170生物1Y11.271 0066-4197生物1Y13.235 1527-8204生物1Y11.568 0066-4227生物1Y12.804 0066-4286生物1Y11.212 1543-5008生物1Y23.460 0092-8674生物1Y31.152 1931-3128生物1Y13.021 1550-4131生物1Y17.350 1934-5909生物1Y23.563 1040-9238生物1Y10.216 0960-9822生物1Y10.992 0955-0674生物1Y14.153 0959-437X生物1Y8.987 1369-5266生物1Y10.333 0959-440X生物1Y9.344 1534-5807生物1Y13.363 0890-9369生物1Y12.075 1088-9051生物1Y11.342 0021-9525生物1Y9.575 1092-2172生物1Y12.585 1097-2765生物1Y14.608 1744-4292生物1Y12.125 1465-7392生物1Y19.527 1552-4450生物1Y16.058 1061-4036生物1Y34.284 1548-7091生物1Y16.874 1471-0056生物1Y27.822 1740-1526生物1Y17.644 1471-0072生物1Y42.198 1545-9985生物1Y12.2731040-4651生物1Y9.293 1544-9173生物1Y12.916 1553-7390生物1Y9.532 1553-7366生物1Y8.978 0163-7827生物1Y8.167 0033-5835生物1Y10.200 0968-0004生物1Y11.572 0962-8924生物1Y12.115 0169-5347生物1Y11.564 0168-9525生物1Y8.689 1360-1385生物1Y9.883 0099-2240生物2Y 3.686 0264-6021生物2Y 5.155 0006-3495生物2Y 4.390 0950-1991生物2Y7.194 0261-4189生物2Y8.993 0021-9193生物2Y 3.940 0021-9258生物2Y 5.328 0022-2836生物2Y 3.871 0270-7306生物2Y 6.057 0305-1048生物2Y7.479 0032-0889生物2Y 6.235 0001-5962数学1Y 2.619 0003-486X数学1Y 4.174 0090-5364数学1Y 3.185 0273-0979数学1Y 3.294 0010-3640数学1Y 2.657 1615-3375数学1Y 1.905 0020-9910数学1Y 2.794 0266-5611数学1Y 1.900 0894-0347数学1Y 3.411 0162-1459数学1Y 2.322 1369-7412数学1Y 3.473 0218-2025数学1Y 2.095 0025-5610数学1Y 2.048 0065-9266数学1Y 2.240 1540-3459数学1Y 2.198 0027-3171数学1Y 2.328 1468-1218数学1Y 2.381 0272-4332数学1Y 1.953 0036-1445数学1Y 3.391 0883-4237数学1Y 3.523 1070-5511数学1Y 3.153 0165-0114数学2Y 2.138 0377-0427数学2Y 1.292 0022-0396数学2Y 1.426 0022-247X数学2Y 1.2250362-546X数学2Y 1.487 0036-1429数学2Y 1.840 1064-8275数学2Y 1.595 0108-7673物理物理－晶体1Y49.926 0001-8732物理1Y19.632 0066-4189物理1Y9.353 0163-8998物理1Y11.964 1040-8436物理1Y 5.167 1126-6708物理1Y 6.019 1863-8880物理1Y 5.814 1433-8351物理1Y10.600 0277-7037物理1Y10.623 1749-4885物理1Y22.869 1745-2473物理1Y15.491 0370-1573物理1Y17.752 0031-9007物理1Y7.328 0079-6565物理1Y 6.742 0034-4885物理1Y11.444 0034-6861物理1Y33.145 0003-6951物理2Y 3.554 0021-9606物理2Y 3.093 1098-0121物理2Y 3.475 1550-7998物理2Y 4.922 0169-409X医学1Y11.957 0065-2776医学1Y7.725 0002-9165医学1Y 6.307 0002-9270医学1Y 6.012 0002-953X医学1Y12.522 1073-449X医学1Y10.689 1600-6135医学1Y 6.433 0003-4819医学1Y16.225 0364-5134医学1Y9.317 0003-4967医学1Y8.111 0003-4932医学1Y7.900 0732-0582医学1Y37.902 0066-4219医学1Y9.940 0147-006X医学1Y24.822 0199-9885医学1Y8.783 1553-4006医学1Y13.500 0362-1642医学1Y22.468 0066-4278医学1Y18.170 0066-4308医学1Y22.750 0163-7525医学1Y7.915 0003-990X医学1Y12.257 0003-9926医学1Y9.813 1079-5642医学1Y7.235 0004-3591医学1Y7.332。
LetPub-JCR2012-期刊
0239-7528 1851-2372 1224-2780 2146-3123 1860-5397 1876-2883 1757-6180 1369-703X 1934-8630 0791-7945 1996-3599 0324-1130 0525-1931 0144-8617 0008-6223 1897-5593 1664-3828 1634-0744 1842-4090 2044-4753 0920-5861 1933-6918 2045-3701 1478-811X 2228-5806 2211-1247 0008-8846 1895-1066 1733-7178 2081-9900 1868-4904 0008-8994 0272-8842 0862-5468 0173-9913 1584-8663 0352-9568 1612-1872 1752-153X 1359-7345 0275-7540 0098-6445 1385-8947 0009-2347 0255-2701 0360-7275 0263-8762 0009-2509 0930-7516 0009-2460 0009-3122 1451-9372 0009-3068 0251-0790
B POL ACAD SCI-TECH B SOC ARGENT BOT BALK J GEOM APPL BALK MED J BEILSTEIN J ORG CHEM BENEF MICROBES BIOANALYSIS BIOCHEM ENG J BIOINTERPHASES BIOL ENVIRON BUILD SIMUL-CHINA BULG CHEM COMMUN BUNSEKI KAGAKU CARBOHYD POLYM CARBON CARDIOL J CARDIORENAL MED CARNETS GEOL CARPATH J EARTH ENV CATAL SCI TECHNOL CATAL TODAY CELL ADHES MIGR CELL BIOSCI CELL COMMUN SIGNAL CELL J CELL REP CEMENT CONCRETE RES CENT EUR J CHEM CENT EUR J ENERG MAT CENT EUR J GEOSCI CENT EUR NEUROSURG CENTAURUS CERAM INT CERAM-SILIKATY CFI-CERAM FORUM INT CHALCOGENIDE LETT CHEM BIOCHEM ENG Q CHEM BIODIVERS CHEM CENT J CHEM COMMUN CHEM ECOL CHEM ENG COMMUN CHEM ENG J CHEM ENG NEWS CHEM ENG PROCESS CHEM ENG PROG CHEM ENG RES DES CHEM ENG SCI CHEM ENG TECHNOL CHEM ENG-NEW YORK CHEM HETEROCYCL COM+ CHEM IND CHEM ENG Q CHEM IND-LONDON CHEM J CHINESE U
大动脉炎患者外周血单个核细胞RT-qPCR内参基因的选择
January 2021Vol.41 No.12021 年 1 月 第 41 卷 第 1 期基础医学与临床Basic & Clinical Medicine文章编号：1001-6325 ( 2021 ) 01-0087-06研究论文大动脉炎患者外周血单个核细胞RT-qPCR 内参基因的选择田苡箫，李菁*收稿日期：2019-11-18 修回日期：2020-04-30*通信作者(corresponding author ) ：lijing6515@ （中国医学科学院北京协和医学院北京协和医院风湿免疫科风湿免疫病学教育部重点实验室国家皮肤与免疫疾病临床医学研究中心，北京100032）扌摘要：目的筛选适于在大动脉炎（TAK ）患者和健康人群（HC ）之间比较外周血单个核细胞（PBMC ）中mRNA 表达水平的内参基因。
方法提取PBMC 中的总RNA,应用RT-qPCR ，分别采用geNorm 、NormFinder 、BestKeeper 3种软 件程序，分析 3-glucuronidase ,GAPDH ,ACTB ,SDHA ,HPRT1,RPL13A ,B2M , YWHAZ 和 PKG1 9 个基因的 mRNA 表达稳定性。
以T-bet 、GATA3和RORC 作为目的基因，比较不同稳定性的内参基因对mRNA 相对丰度的影响。
结果geNorm 筛选得到的基因组合为B 2M-SDHA , Nor^nFinder 和BestKeeper 筛选出最稳定的内参基因均为HPRT1 ； 3种方法均显示GAPDH 的稳定性较差。
结论自身免疫病患者在接受免疫抑制药物治疗时,原本稳定表达的基因可能会 上调或下调;在样本量较小时，稳定性更好的内参基因可能更有助于检测组间差异。
关键词：大动脉炎;实时定量聚合酶链式反应;RNA 稳定性；内参基因选择中图分类号:R593.2 文献标志码:AValidation of reference genes for the normalization of the RT-qPCRin peripheral blood mononuclear cells of patients with Takayasu arteritisTIAN Yi-xiao ， LI Jing *(Department of Rheumatology and Immunology , Key Laboratory of Rheumatology and Clinical Immunology , Ministry of Education ,National Clinical Research Center for Dermatologic and Immunologic Diseases ( NCRC-DID ),Peking Union Medical College Hospital , CAMS & PUMC , Beijing 100032, China)Abstract ： Objective To validate proper reference genes for quantitative real-time polymerase chain reaction ( RT-qPCR) used for comparing mRNA expression levels in Takayasu arteritis" (TAK) and healthy controls' ( HC ) pe ripheral blood mononuclear cells ( PBMC ). Methods Total RNA in PBMCs was extracted and used RT-qPCR to determine the profiles of 9 candidate genes , including 0-glucuronidase, GAPDH , ACTB , SDHA , HPRT1, RPL13A , B2M , YWHAZ and PKG1. Then compared their transcription stability by geNorm , NormFinder , and Best Keeper. Afterwards , with T-bet , GATA3 and RORC as the targeted genes , explored the influence of reference genes with different stability on mRNA relative abundance. Results The gene combination of B2M-SDHA was selected bygeNorm , and HPRT1 was the most stable one in analysis results of NormFinder and BestKeeper , while GAPDH was less stable. Conclusions Genes that have been expressed stably may be upregulated or downregulated whenpatients with autoimmune diseases received immunosuppressive drugs. When the sample size is small ， the more sta ble internal reference may facilitate the identification of inter-groups difference.Key words : Takayasu arteritis ； real-time polymerase chain reaction ； RNA stability ； selection of reference gene88基础医学与临床Basic&Clinical Medicine2021.41(1)反转录实时荧光定量聚合酶链式反应（reverse quantitative real-time polymerase chain reaction,RT-qPCR）是目前分析基因表达水平的黄金标准，却经常表现出重复性欠佳的问题，选取合适的内参基因有助于改善这一情况［1］。
人基质质控血清
注释：
®：注册商标
(1). 只适用于德国。
根据德国内科医生联邦议院的方针制订范围(中文说明已略，如需请另行参见英文说明)。
(2). 德国内科医生联邦议院官方认可的参考实验室测定的浓度值。
(3). DGKC：德国临床化学协会
(4). IFCC：国际临床化学联盟
(5). SCE：斯堪的纳维亚酶委员会
使用说明
朗道的人基质质控血清为冻干品，用于临床准确性或者重复性质量控制。
朗道供应2种水平的质控血清。
赋值
每一批质控血清都要送到参考实验室，根据国际参考标准进行赋值。
若没有国际参考标准，就使用参考方法。
朗道也将质控血清送到全世界3000多家实验室，然后将结果用相同的统计分析赋值。
质控范围值是平均值±2S.D.。
该结果非常准确可靠，实验室尽可放心使用。
准备
1. 小心打开瓶盖，避免内容物的任何损失。
2. 在20-25℃的室温下，准确量取5ml蒸馏水复溶1瓶质控血清。
3. 盖上橡皮塞，拧紧瓶盖，使用前避光放置30分钟。
4. 轻轻旋转，确保内容物完全溶解。
5. 将小瓶倒置，确保所有的冻干物完全溶解。
6. 勿摇晃小瓶。
复溶后的血清既可以用于手工测试，也可以用于全自动生化分析仪。
该血清只能按照上述步骤复溶。
稳定性
该血清自生产之日起，在4℃下保存可以稳定4年。
效期标在试剂盒的侧面。
该血清一旦复溶，在25℃下可以稳定24小时，在4℃下可以稳定7天，在-20℃至少可以稳定1个月（见受限情况）。
外泌体在风湿病中作用的研究进展
外泌体在风湿病中作用的研究进展作者：郭晓萱李大可来源：《风湿病与关节炎》2023年第10期【摘要】外泌体是一种纳米囊泡，不同类型的细胞均可以释放，在正常情况下可以从血液、尿液等多种体液中分离得到。
外泌体及其组成成分在细胞间通讯中起着重要作用。
现如今越来越多的研究已经证实，外泌体可以将其所含成分转移到受体细胞中，从而改变受体细胞的生物活性，与各种风湿病的病理生理过程有关，并在疾病治疗和诊断中有着潜在作用。
【关键词】风湿病；外泌体；微小RNA；研究进展；综述外泌体是一种直径为30～120 nm的由磷脂双分子层膜包裹的囊泡，可以参与细胞间的信息传递［1］。
外泌体的成分包括DNA、RNA、蛋白质及脂质物质，其中微小RNA （miRNA）是一种长度为21～23个核苷酸的单链非编码小分子RNA，在人体中通过转录后抑制蛋白质编码基因的表达参与多种生物学途径的调节［2］。
长链非编码RNA（lncRNA）是一类长度超过200个核苷酸的非编码RNA，与多种自身免疫性疾病的发生、发展有关。
近期的研究表明，外泌体或许可以作为疾病诊断和预后的新生物标志物，并为多种疾病提供新的治疗方向。
1 外泌体与类风湿关节炎（rheumatoid arthritis，RA）在RA的病理过程中，外泌体主要参与抗原呈递、炎性细胞因子和miRNA的传递以及成纤维样滑膜细胞（FLS）的激活［3］。
RA患者滑膜外泌体具有较高的破骨潜能，这可能导致了其特征性的骨质侵蚀［4］。
FLS来源的外泌体可显著诱导T细胞分化，使辅助性T细胞（Th17）增加，调节性T细胞（Treg）细胞减少，通过调节Treg/Th17平衡影响RA临床症状，因此，可以作为RA的潜在治疗靶点［5］。
程明等［6］实验发现，人骨髓间充质干细胞（hBMSCs）来源外泌体miRNA-320a对CXC趋化因子配体9有负调控作用，从而抑制RA-FLS增殖和迁移能力。
外泌体来源的miR-155可能通过对趋化因子的调节而促进炎性细胞在RA滑膜中的募集和滞留，进而参与RA的发病［7］。
GDC-0834_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jun.-08-2017Print Date:Jun.-08-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :GDC-0834Catalog No. :HY-15427CAS No. :1133432-49-11.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:GDC 0834; GDC0834Formula:C33H36N6O3SMolecular Weight:596.74CAS No. :1133432-49-14. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
医学词典
医学词典.txt人和人的心最近又最远，真诚是中间的通道。
试金可以用火，试女人可以用金，试男人可以用女人--往往都经不起那么一试。
A145N-乙氧碳基氨甲基-L-异亮氨酸A2780人卵巢癌细胞细胞系A549人肺腺癌细胞系aberrant异常abortion流产acceleration加速access访问accessible可访问的acetylaminofluorene乙酰氨基芴（致癌物）aclacinon山之内的商品名adriblastine阿霉素affect影响affection疾患、病、影响alafloxacin阿拉沙星albacort地塞米松amenorrhea闭经amerantrone蒽二酮aminoazotoluene氨基偶氮甲笨（肝脏致癌剂）amniocentesis羊膜穿刺amnion羊膜amnioscope羊膜镜amnioscopy羊膜镜检查amniotomy人工破膜amoxicillin阿莫西林;羟氨苄青霉素amphiregulin双调素，为表皮生长因子家族的成员之一ampulla壶腹部anastomosis吻合术anastrozole阿纳托唑，选择性非甾体类芳香化酶抑制剂。
androblastoma男性母细胞瘤androgen雄激素Anesthetist麻醉医师aneuploid非整倍体angiostatin血管抑制素anitratum硝酸盐阴性（不动杆菌）anovulation不排卵anteflexion前屈antibody抗体antigen抗原antineoplaston抗肿瘤治疗antiretroviral抗逆转录病毒的antisignaling抗信号药物appendix阑尾approximation对合arabitin阿糖腺苷，腺嘌呤阿糖甙Aredia阿可达，帕米膦酸钠（pamidronate）的商品名，Novartis公司出品arimedex芳香化酶抑制剂arimidex新的芳香化酶抑制剂arteriography动脉造影atelectasis肺不张atopic变态反应性autocrineloops自泌环autoinvasive自身侵袭性autosome常染色体AY62013环氧甘醚，乙环氧啶azimexone羧胺氰丙啶（BRMs)B16黑色素瘤细胞系（小鼠）BAK椎体间融合器Ball公司名称;波尔公司;金属制品;网址baseline基线baumanii鲍曼不动杆菌BCDFB细胞分化因子（BRMs)bednet臭虫behavior行为Bel7402人肝癌细胞系Biaoroubixing表阿霉素bioassay生物测定biopsy活检boolean布尔bromoacetoxylphenylhexan溴乙酰己烷雌酚，内消旋3bromodeoxyuridine溴脱氧尿嘧啶，在DNA合成过程中渗入细胞，用于作为进入或经历DNA合成期（S期）的标记，代表DNA合成水平bronchicanis支气管败血症（Bordetella bronchiseptica支气管败血症博代氏菌）BSLi西非单叶豆凝集素，对B型血球专一BSN次硝酸铋（诱导正常组织产生金属硫蛋白，降低化疗药物毒性）；bowel sounds normal 肠鸣音正常BTIC氯乙基三氮烯咪唑酰胺BU2231A泰来霉素（博莱霉素衍生物，是一种霉菌产生的糖肽化合物）C12U核酸抗癌剂干扰素诱导剂cabergoline卡麦角林（镇痛药）cackexia恶液质CAI羧基胺基咪唑，是一种细胞信号传导抑制剂，能够阻滞配体受体依赖性Ca2+的内流，改变包括内皮细胞在内的多种细胞的生物行为，如运动、侵袭、酶解和构建血管等，在体内外抑制血管形成calciifolinas亚叶酸calcoacelicus醋酸钙（不动杆菌）Calprotectin钙卫蛋白：钙卫蛋白是近年发现的与钙结合的不均一的复合蛋白质，由2重链及1轻链构成，主要来源于嗜中性粒细胞和单核细胞，分布于粒单细胞、上皮细胞、角质细胞内及各种组织和体液中，具有抗微生物、抗增殖等多种生物学功能。
ADC药物研发现状
Title Originator Highest Dev Status 111In-capromab pendetide Cytogen Corp Launched111In-imciromab pentetate Janssen Biotech Inc Launched131I-chTNT-1/B Peregrine Pharmaceuticals Inc Launched131I-metuximab Fourth Military Medical University PLA Launchedbrentuximab vedotin Seattle Genetics Inc Launchedgemtuzumab Wyeth Research Launchedibritumomab tiuxetan IDEC Pharmaceuticals Corp Launchedtrastuzumab emtansine Genentech Inc LaunchedATL-101, ATLAB Cornell University Phase 3 Clinical inotuzumab ozogamicin Wyeth Research Phase 3 Clinical oportuzumab monatox (intratumoral, head and neck cancer), Viventia University of Zurich Phase 3 ClinicalRIGS CC49Navidea Biopharmaceuticals Inc Phase 3 ClinicalABT-414Abbott Laboratories Phase 2 ClinicalCDX-1401Celldex Therapeutics Inc (pre-merger)Phase 2 Clinical glembatumumab vedotin CuraGen Corp Phase 2 ClinicalLMB-2National Cancer Institute Phase 2 Clinical lorvotuzumab mertansine ImmunoGen Inc Phase 2 Clinical moxetumomab pasudotox National Cancer Institute Phase 2 Clinical oportuzumab monatox (intravesicular, bladder cancer), Viventia University of Zurich Phase 2 ClinicalPSMA-ADC Cytogen Corp Phase 2 ClinicalRG-7593Genentech Inc Phase 2 ClinicalRG-7596Genentech Inc Phase 2 ClinicalSAR-3419ImmunoGen Inc Phase 2 Clinical212-Pb-TCMC-trastuzumab National Cancer Institute Phase 1 ClinicalActimab-A PDL BioPharma Inc Phase 1 ClinicalAGS-16M8F Agensys Inc Phase 1 Clinicalanti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-Hodgkin's lymphoma), Wayne State University/Barbara Ann KarmanosCancer Institute Barbara Ann Karmanos Cancer Institute Phase 1 ClinicalASG-5ME Agensys Inc Phase 1 ClinicalBAY-79-4620MorphoSys AG Phase 1 Clinical citatuzumab bogatox Viventia Biotech Inc Phase 1 Clinical doxorubicin-loaded anti-EGFR immunoliposomes (solid tumors), UniversityHospital Basel University Hospital of Basel Phase 1 ClinicalHuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome),Targa Therapeutics Memorial Sloan-Kettering Cancer Center Phase 1 ClinicalIMGN-529ImmunoGen Inc Phase 1 ClinicalIMGN-853ImmunoGen Inc Phase 1 ClinicalIMMU-132Immunomedics Inc Phase 1 Clinical labetuzumab-SN-38Immunomedics Inc Phase 1 ClinicalNHS-IL-12National Cancer Institute Phase 1 ClinicalRG-7450Genentech Inc Phase 1 ClinicalRG-7458Genentech Inc Phase 1 Clinical RG-7598Genentech Inc Phase 1 Clinical RG-7599Genentech Inc Phase 1 Clinical RG-7600Genentech Inc Phase 1 Clinical RG-7636Genentech Inc Phase 1 Clinical SAR-566658ImmunoGen Inc Phase 1 Clinical T-Guard University Medical Center St Radboud Phase 1 Clinical vorsetuzumab mafodotin Seattle Genetics Inc Phase 1 Clinical 131I-catuximab (colorectal cancer), Pacific Meinuoke Fourth Military Medical University PLA Discovery177Lu-tetraxetan-tetulomab (non-Hodgkin's lymphoma), Nordic Nanovector Nordic Nanovector AS Discovery227Th-epratuzumab (hematological cancer), Algeta Algeta ASA Discovery227Th-rituximab (cancer), Algeta Algeta ASA Discovery227Th-trastuzumab (cancer), Algeta Algeta ASA Discovery4s3-0014s3 Bioscience Inc Discovery4s3-0024s3 Bioscience Inc Discovery64Cu-NOTA-ALT-836Altor BioScience Corp DiscoveryAA-A225Actinium Pharmaceuticals Inc Discovery AbGn-107AbGenomics Corp Discovery Actimab-B Fred Hutchinson Cancer Research Center Discovery Actimab-C Actinium Pharmaceuticals Inc Discovery Actimab-P Actinium Pharmaceuticals Inc Discovery adalimumab + anti-Ang2 Zybody (rheumatoid arthritis/inflammatory boweldisease), Zyngenia Zyngenia Inc DiscoveryAGS-15E ADC Agensys Inc DiscoveryAGT-160ArmaGen Technologies Inc DiscoveryAGT-185ArmaGen Technologies Inc DiscoveryAGT-190ArmaGen Technologies Inc Discovery amanitin-trastuzumab conjugate (cancer), Heidelberg Pharma Heidelberg Pharma Holding Ltd Discoveryanti-CD133-immunotoxin conjugates (photochemical internalization, cancer),PCI Biotech PCI Biotech Holding ASA Discoveryanti-ET8R-MC-vc-PAB-MMAE Genentech Inc Discoveryanti-NaPi3b antibody-drug conjugate (cancer), Genentech/Roche Genentech Inc Discovery antibody drug conjugates (cancer), Sanofi Sanofi Discovery antibody-drug conjugates (cancer), ADC Therapeutics ADC Therapeutics Sarl Discovery antibody-drug conjugates (cancer), Seattle Genetics/Oxford BioTherapeutics Seattle Genetics Inc Discovery antibody-drug conjugates (TAP, cancer), Lilly Eli Lilly & Co Discovery antibody-IFN lambda conjugates (cancer), Immunomedics Immunomedics Inc Discovery anticancer therapy (TAP technology), Amgen Amgen Inc DiscoveryAPH-0912Aphios Corp Discovery Aurixin BioIntegrator DiscoveryAZ-05Allozyne Inc Discovery BIOO-1BIOO Therapeutics DiscoveryBIOO-2BIOO Therapeutics Discovery BIOO-3BIOO Therapeutics Discovery BIOO-4BIOO Therapeutics Discovery BIOO-5BIOO Therapeutics Discovery BIOO-6BIOO Therapeutics Discovery BIOO-7BIOO Therapeutics Discovery botulinum toxin B inhibitor (injectable, heteropolymer mAbs, botulism),Immunome Immunome Inc Discovery BT-2111biOasis Technologies Inc Discovery C2-2b-2b Immunomedics Inc Discovery CDX-014CuraGen Corp Discovery chiHEA-125-Ama Heidelberg Pharma Holding Ltd Discovery CK-22-(20)-(20)Immunomedics Inc Discovery complement factor H-derived short consensus repeat-antibody constructs(infection), LysoVac University of Innsbruck Discovery Cymac-001Cytoguide ApS Discovery CYP-Ab Cytune Pharma Discovery D2C7-based immunotoxins (glioma), Duke University Duke University Discovery EGFR modulators (antibody conjugates, PIT, cancer), Aspyrian Aspyrian Therapeutics Inc Discovery engineered cysteine drug conjugates mAbs (cancer), Seattle Genetics Seattle Genetics Inc Discovery epratuzumab-SN-38Immunomedics Inc Discovery ETBs (cancer), Molecular Templates/ Imclone Molecular Templates Inc Discovery Fluorescent-labeled bevacizumab (imaging, ocular disease), Mivenion mivenion Gmbh Discovery gemcitabine + paclitaxel (prodrug, nanomAb, cancer), ImmunePharmaceuticals Immune Pharmaceuticals Corp Discovery Herceptin:Endostatin-P125A University of Miami Discovery hLL1-CL2A-SN-38Immunomedics Inc Discovery hPAM4-CL2A-SN-38Immunomedics Inc Discovery human monoclonal antibody-toxin conjugates (myocardial infarction), Celdara Celdara Medical LLC Discovery HuMax-TF-ADC Genmab A/S Discovery IFNalpha-fused mAbs (HBV infection), Roche Roche Holding AG Discovery IL-13 receptor alpha 2 inhibitors (iv, cancer), Pfizer Pfizer Inc Discovery IMGN-289ImmunoGen Inc Discovery intracellular antibodies (Intraphilin, inflammatory diseases/infectiousdiseases/ophthalmic diseases), Permeon Biologics Permeon Biologics Inc Discovery mapp-66Mapp Biopharmaceutical Inc Discovery MB-2003Mapp Biopharmaceutical Inc Discovery monoclonal antibody-drug conjugates, Chirogenix/ImmunoGen/Celltrion Chirogenix Co Ltd Discovery MP-Ter-ADC MediaPharma Srl Discovery N01-OX2Intellect Neurosciences Inc Discovery PC-91ProCell Therapeutics Inc Discovery ProstaLite PhotoBiotics Ltd Discoveryrecombinant mAb-biocide fusion proteins (oral/Directed Biocide,cryptosporidium infection), ioGenetics ioGenetics Inc Discovery SGN-CD33A Seattle Genetics Inc Discovery SGN-LIV1A Seattle Genetics Inc Discovery SL-101Stemline Therapeutics Inc Discovery SYD-983Synthon Biopharmaceuticals Discovery T01-OX2Intellect Neurosciences Inc Discovery TBL-0306L Transgene Biotek Ltd Discovery TBL-0306M Transgene Biotek Ltd Discovery TBL-0805E Transgene Biotek Ltd Discovery thio-trastuzumab-mpeo-DM1Genentech Inc Discovery trastuzumab-PNU-159682 antibody-drug conjugate (cancer), Genentech Genentech Inc Discovery veltuzumab-IFN alpha 2b conjugate (cancer), IBC/Immunomedics IBC Pharmaceuticals Inc Discovery BIIB-015Biogen Inc Suspended Pretarget technology (gastrointestinal adenocarcinoma), NeoRx Poniard Pharmaceuticals Inc Suspended125I-AnnA1 IgG Sidney Kimmel Cancer Center No Development Reported131I-CC49-SCA Enzon Labs Inc No Development Reported177Lu-capromab pendetide Cytogen Corp No Development Reported90Y-capromab pendetide Cytogen Corp No Development Reported99mTC-BERH2Medac GmbH No Development Reportedanti-CD133-vcMMAF Seattle Genetics Inc No Development Reportedanti-CD22 antibody drug-conjugates, Medarex/BMS Medarex Inc No Development Reportedanti-PSMA antibody-drug conjugates (cancer), Medarex Medarex Inc No Development Reportedantibody-drug conjugates (solid tumors), Daiichi Sankyo Seattle Genetics Inc No Development ReportedAVE-9633ImmunoGen Inc No Development Reportedbectumomab Immunomedics Inc No Development ReportedCA125/MUC16-targeting antibody-drug conjugate (ovarian cancer),Genentech Genentech Inc No Development Reportedcathepsin B-sensitive prodrugs, BMS Bristol-Myers Squibb Pharmaceutical ResearchInstituteNo DevelopmentReportedCC49 humanized radioimmunoconjugates, National Cancer Institute,University of Alabama at Birmingham National Cancer Institute No Development ReportedCD4-BFFI Roche Holding AG No Development ReportedCHB-111ViRexx Medical Corp No Development ReportedCHT-25University College London No Development ReportedCMD-193Wyeth No Development ReportedCNTO-95 immunoconjugates (cancer), Centocor Janssen Biotech Inc No Development Reportedconjugated PEI/anti-CD133 mAb plasmid-based gene therapy (brain tumor),Discovery genomics Discovery Genomics Inc No Development ReportedcT84.66City of Hope No Development Reporteddelta 9-cadherin targeting antibody (gastric cancer), Actinium Helmholtz Zentrum München No Development Reporteddiphtheria toxin, RCT Research Corporation Technologies No Development Reporteddoxorubicin-C225 conjugate (STEALTH), SEQUUS SEQUUS Pharmaceuticals Inc No Development ReportedDTPA-BrE-3University of Colorado System No Development ReportedDXL-625InNexus Biotechnology Inc No Development ReportedG3.519-PAP-S Tanox Inc No Development ReportedhuHMFG1-caspase Antisoma plc No Development ReportedIMGN-007ImmunoGen Inc No Development ReportedIMGN-009ImmunoGen Inc No Development Reportedimmunoconjugate (cancer MN), Bayer Bayer AG No Development ReportedImmuRAID-AFP-99mTc, Immunomedics Immunomedics Inc No Development ReportedIMTOX 22-97A University of Texas Southwestern MedicalCenterNo DevelopmentReportedKSB-201KS Biomedix Holdings plc No Development ReportedLA22-radioimmunoconjugates (cancer), Welson/Peking University Welson Pharmaceuticals Inc No Development Reportedlabetuzumab Immunomedics Inc No Development ReportedLMB-1, NIH National Institutes of Health No Development ReportedLu-177-trastuzumab Tarbiat Modares University No Development ReportedLymphoScan Immunomedics Inc No Development ReportedMDX-11Medarex Inc No Development ReportedMDX-1203Medarex Inc No Development ReportedMDX-1206Medarex Inc No Development Reportedmonoclonal-porphyrins, Quadra Logic QLT Inc No Development Reportedmonoclonals, Quest Quest Biotechnology Inc No Development ReportedNogo receptor modulators, Biogen Idec Yale University No Development ReportedONS-1210Oncobiologics Inc No Development ReportedOP-06 program (cancer), Onco-Pharmakon Onco-Pharmakon Inc No Development Reportedpaclitaxel analogs and immunoconjugates (cancer), Bioxel Bioxel Pharma Inc No Development ReportedPE38-conjugated anti-CD30 immunotoxin, NCI National Cancer Institute No Development Reportedprostate-specific MAb, NIH National Institutes of Health No Development ReportedR-1549The UK Imperial Cancer Research Fund No Development Reportedradiolabeled Tx3.833Beth Israel Deaconess Medical Center No Development Reportedscu-PA-59D8Bristol-Myers Squibb Co No Development ReportedSGN-17/19Seattle Genetics Inc No Development Reportedtaxane-monoclonal antibody conjugates, ImClone ImClone Systems Inc No Development Reportedtranscobalamin (vitamin B12) receptor-targeting mAbTCR23-saporinconjugate (cancer), Kyto Kyto Biopharma Inc No Development Reportedtrastuzumab-autophilic peptide conjugate (breast cancer), InNexusBiotechnology InNexus Biotechnology Inc No Development Reportedtrastuzumab-MC-vc-PAB-MMAF Genentech Inc No Development ReportedTRP-targeted antibody conjugate (Yttrium 90/MX-DTPA), SomantaPharmaceuticals Immunodex Inc No Development Reportedtucotuzumab celmoleukin EMD Lexigen Research Center Corp No Development ReportedVB4-011Viventia Biotech Inc No Development ReportedVB6-011Viventia Biotech Inc No Development ReportedVB6-050Viventia Biotech Inc No Development ReportedXomaZyme-791XOMA Corp No Development Reportednofetumomab Poniard Pharmaceuticals Inc Withdrawn 131I-81C6Duke University Discontinued 131I-ImmuRAIT-HCG, Immunomedics Immunomedics Inc Discontinued B-B4-DC1ImmunoGen Inc Discontinued CC49 radioimmunoconjugates, University of Alabama at Birmingham University of Alabama at Birmingham Discontinued CD5 monoclonals/RIPs, Italfarmaco Italfarmaco SpA Discontinued CVX-045CovX Pharmaceuticals Inc Discontinued CVX-060CovX Pharmaceuticals Inc Discontinued CVX-241CovX Pharmaceuticals Inc Discontinued CVX-343CovX Pharmaceuticals Inc Discontinued doxorubicin-BR96 conjugate, BMS Bristol-Myers Squibb Co Discontinued doxorubicin-CEA conjugate, Immunomedics Immunomedics Inc Discontinued doxorubicin-LL2 conjugate, Immunomedics Immunomedics Inc Discontinued FAP5-DM1Boehringer Ingelheim Corp Discontinued FGFR4-CovX-Body CovX Pharmaceuticals Inc Discontinued HuM-195-Bi-213PDL BioPharma Inc Discontinued human placental growth factor 1-CVX-2000 monoclonal antibody conjugatedtherapeutic (CovX-body, cancer), CovX CovX Pharmaceuticals Inc Discontinued huN901-CC-1065ImmunoGen Inc Discontinued huN901-DC1ImmunoGen Inc Discontinued ImmuRAID-HCG-99mTc, Immunomedics Immunomedics Inc Discontinued ImmuRAIT-CEA-rhenium-188, Immunomedics Immunomedics Inc Discontinued MDX-214Medarex Inc Discontinued MEDI-547MedImmune LLC Discontinued MLN-2704Cornell University Discontinued Oncolym Peregrine Pharmaceuticals Inc Discontinued Oncolysin B Dana-Farber Cancer Institute Inc DiscontinuedOncolysin CD6Dana-Farber Cancer Institute Inc Discontinued Oncolysin M Dana-Farber Cancer Institute Inc Discontinued Oncolysin S Dana-Farber Cancer Institute Inc Discontinued Oncopurge Poniard Pharmaceuticals Inc Discontinued rhenium-188-LL2, Immunomedics Immunomedics Inc Discontinued SMART ABL-364Novartis AG Discontinued targeted ranpirnase conjugates (cancer), Alfacell Tamir Biotechnology Inc DiscontinuedHighest Dev Status。
Oracle Health Sciences InForm EDC 平台介绍说明书
Oracle Health Sciences InForm EDC PlatformDeliver Higher-Quality Data, Faster and with Less Effort, Cost and Risk INFORM AT A GLANCEDrive effciencies with integratedand automated workfows andself-service, one-click studydeployment Integration with Oracle Argus increases productivity and speeds safety reporting 50%Cut weeks or months off time to database lock with InForm Data ViewerIntegration with Oracle IRT RTSMsolution reduces data entryand data reconciliation acrossapplications by up to 90%#1 in global site satisfaction means faster study startups with less risk #1Integration with Data Management Workbench reduces time and effort to clean and transform data by up to 60%INCREASE EFFICIENCY • Design trials in just a few days and auto-deploy with one click• Assess , review , and lock a site or entire study in minutes• Streamline workfows with fully integrated CDM, IRT , medical coding, safety and moreIMPROVE DATA QUALITY• Identify problems and take corrective action more quickly with real-time visibility to data• Conduct effective risk-based monitoring• Incorporate mid-study revisions without migrating data like other EDC systemsREDUCE COST• Integrated workfows require far less time and manualeffort50% • Streamlined monitoring and faster time to database lockreduces costly and unnecessary steps• Flexible pricing and delivery models bring capabilities ofmarket-leading InForm EDC to virtually any organizationBROADEST PLATFORMInForm offers the industry’s broadest platform of integrated systems and workfows to drive greater efficiency and data quality while reducing costClinical Data ManagementPhysiologic DataIRT ePROCTMS Clinical BiomarkersMedication AdherenceInForm Site Payments SafetyeTMF Medical Coding Risk-based MonitoringORACLE HEALTH SCIENCES INFORM EDC PLATFORMThe market-leading EDC system and the #1 preferred choice of investigator sites worldwide.For more information visit our clinical data management solutionsJoin our communitiesCopyright © 2015, Oracle and/or its affiliates. All rights reserved. Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners. 150916。
德谷门冬双胰岛素注射液治疗2_型糖尿病临床效果及安全性探讨
DOI：10.16658/ki.1672-4062.2023.17.098德谷门冬双胰岛素注射液治疗2型糖尿病临床效果及安全性探讨林生，谢平，陈予福州市长乐区人民医院内分泌科，福建福州350200[摘要]目的研究德谷门冬双胰岛素注射液治疗2型糖尿病的临床效果及安全性。
方法选取于2022年7月—2023年4月福州市长乐区人民医院收治的2型糖尿病患者98例为研究对象，采用随机抓阄法分为两组，每组49例。
两组均联用常规降糖药物治疗，对照组采用甘精胰岛素注射液治疗，观察组采用德谷门冬双胰岛素注射液治疗。
对比两组临床治疗效果、临床症状好转时间和胰岛素用量情况、糖代谢指标、胰岛素功能指标、不良反应发生情况、心血管不良事件发生情况。
结果观察组总有效率高于对照组，差异有统计学意义（P<0.05）。
观察组尿酮体转阴时间、血糖达标时间、胰岛素用量均优于对照组，差异有统计学意义（P< 0.05）。
观察组空腹血糖、餐后2 h血糖、糖化血红蛋白均低于对照组，差异有统计学意义（P<0.05）。
观察组胰岛β细胞功能指数高于对照组，胰岛素抵抗指数、空腹胰岛素低于对照组，差异有统计学意义（P<0.05）。
两组恶心呕吐、倦怠乏力、低血糖总发生率比较，差异无统计学意义（P>0.05）。
两组心绞痛、心力衰竭总发生率比较，差异无统计学意义（P>0.05）。
结论德谷门冬双胰岛素注射液治疗2型糖尿病临床效果显著优于甘精胰岛素注射液，但是治疗安全性无显著变化。
[关键词] 2型糖尿病；德谷门冬双胰岛素注射液；不良反应；心血管不良事件[中图分类号] R59 [文献标识码] A [文章编号] 1672-4062（2023）09（a）-0098-04Discussion on the Clinical Effect and Safety of Insulin Degludec and Insu⁃lin Aspart Injection in the Treatment of Type 2 Diabetes MellitusLIN Sheng, XIE Ping, CHEN YuDepartment of Endocrinology, Changle District People's Hospital, Fuzhou, Fujian Province, 350200 China[Abstract] Objective To study the clinical effect and safety of insulin degludec and insulin aspart injection in the treatment of type 2 diabetes mellitus. Methods A total of 98 patients with type 2 diabetes admitted to Fuzhou Changle District People's Hospital from July 2022 to April 2023 were selected as the study objects and divided into two groups with 49 cases in each group by random lottery method. Both groups were treated with conventional hypoglycemic drugs, the control group was treated with insulin glargine injection, and the observation group was treated with Degu asparton double insulin injection. The clinical therapeutic effect, time of improvement of clinical symptoms, insulin dosage, glucose metabolism index, insulin function index, occurrence of adverse reactions and cardiovascular adverse events were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). The time of urine ketone body turning negative, blood glucose reaching standard and insulin dosage in observation group were better than those in control group, and the differences were statistically significant (P<0.05). Fasting plasma glucose, 2-hour postprandial blood glucose and glycated hemoglobin in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). The function index of islet β cells in observation group was higher than that in control group, the insulin resistance index and fasting insulin was lower than that in control group, the dif⁃ference was statistically significant (P<0.05). There was no statistically significant difference in the total incidence of [作者简介]林生（1981-），男，本科，副主任医师，研究方向为糖尿病及其并发症的相关临床研究。
E14 Guideline (R3) - questions and answers说明书
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 555525 January 2016EMA/CHMP/ICH/310133/2008Committee for Human Medicinal ProductsICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (R3) - questions and answersStep 5E14 Q&As (R3) Document HistoryICH guideline E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (R3) - questions and answersICH guideline E14 (R3) - questions and answersTable of contents1E lectrocardiograms methodology (4)2G ender (9)3P ositive control (10)4S tudy design (12)5U se of concentration response modeling of QTc data (13)6S pecial cases (16)7E lectrocardiograms monitoring in late stage clinical trials (17)ICH guideline E14 (R3) - questions and answers1Electrocardiograms methodologyICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 4/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 5/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 6/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 7/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 8/202GenderICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 9/203Positive controlICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 10/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 11/204Study designICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 12/205Use of concentration response modeling of QTc dataICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 13/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 14/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 15/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 16/20 6 Special cases6.1 March2014 The ICH E14 Guideline states that in certain cases a conventional thoroughQT study might not be feasible. In suchcases what other methods should beused for evaluation of QT/QTc andproarrhythmic potential? In certain cases the conventional “thorough QT/QTc” study design (a crossover study in healthy volunteers with short-term administration of the usual maximum dose and one higher dose with placebo and positive control) might need to be modified for a drug or active metabolite with a long half-life or delayed QT effect, or because of safety, tolerability or practical issues that preclude use in healthy subjects. In most cases alternative designs can be used that may affect power considerations, but do notcompromise study interpretation. For example, multiple doses can be studied in aparallel design trial or can use patients with the disease for which the drug is intendedrather than healthy volunteers.Where a placebo-controlled comparison using appropriate doses is not possible,alternative study d esigns should incorporate as many of the usual “thorough QT/QTc”design features as possible, and the quality and extent of the pre-clinical evaluation (ICHS7B Guideline) is particularly critical. Other useful supplementary data might includeintensive ECG data acquisition in early phase single or multiple ascending dose studies,utilisation of concentration-response analysis, and evaluation of exposures that aregreater than are anticipated with the intended marketed dose.A single dose of a positive control is generally sufficient, even if it precedes theinvestigational drug treatment. In the absence of a positive control, there is reluctanceto draw conclusions of lack of an effect; however, if the upper bound of the two-sided90% confidence interval around the estimated maximal effect on QTc is less than 10 ms,it is unlikely to have an actual mean effect as large as 20 ms.When a thorough QTc study of usual or modified design is not feasible, the intensity oflate phase ECG monitoring will be dependent upon the quality and extent of the non-clinical and clinical evaluation. In situations where it is not possible to study higherexposures than are anticipated with the intended marketed dose, more intensive ECGmonitoring might be necessary during Phase 3 trials. When the non-clinical and early7Electrocardiograms monitoring in late stage clinical trialsICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 17/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 18/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 19/20ICH guideline E14 (R3) - questions and answersEMA/CHMP/ICH/310133/2008 Page 20/20。
依达拉奉右莰醇联合溶栓治疗对急性缺血性脑卒中患者的神经功能保护作用及机制研究
依达拉奉右莰醇联合溶栓治疗对急性缺血性脑卒中患者的神经功能保护作用及机制研究陈小妮，谭会会，陈蕊西安市第三医院神经内科，陕西西安710021【摘要】目的探讨依达拉奉右莰醇联合溶栓治疗对急性缺血性脑卒中患者的神经功能保护作用及其作用机制。
方法选择2020年12月至2022年1月西安市第三医院神经内科收治的90例急性缺血性脑卒中患者展开研究，按随机数表法分为观察组和对照组各45例。
两组患者均接受静脉溶栓治疗，对照组患者在溶栓后使用依达拉奉注射液治疗，观察组患者溶栓后则使用依达拉奉右莰醇注射用浓溶液治疗，两组均治疗两周。
比较两组患者治疗两周后的临床疗效，治疗前及治疗两周后的美国国立卫生研究院卒中量表(NIHSS)评分、巴氏量表(Barthel 指数)、血清谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、丙二醛(MDA)、肿瘤坏死因子-α(TNF -α)、白细胞介素-1β(IL -1β)水平及治疗期间的不良反应发生情况。
结果治疗后，观察组患者的临床疗效总有效率为91.11%，明显高于对照组的73.33%，差异有统计学意义(P <0.05)；治疗后，观察组患者的NIHSS 评分为(7.90±1.34)分，明显低于对照组的(9.42±1.68)分，Barthel 指数为(67.14±5.18)分，明显高于对照组的(62.89±4.67)分，差异均有统计学意义(P <0.05)；治疗后，观察组患者的血清GSH-Px 、SOD 水平分别为(234.09±21.57)mg/L 、(95.23±17.45)U/mL ，明显高于对照组的(205.63±18.32)mg/L 、(79.56±14.18)U/mL ，血清MDA 、TNF -α、IL -1β水平分别为(4.65±0.89)μmol/L 、(86.52±15.40)ng/L 、(86.52±15.40)pg/mL ，明显低于对照组的(6.42±1.10)μmol/L 、(113.67±16.05)ng/L 、(288.51±31.27)pg/mL ，差异均有统计学意义(P <0.05)；两组患者治疗期间均无明显不良反应发生。
康莱特注射液联合化疗治疗晚期肺腺癌的临床研究
康莱特注射液联合化疗治疗晚期肺腺癌的临床研究张育荣，桑蝶，范善民，赵晓慧（北京市朝阳区三环肿瘤医院内科，北京100122）摘要：目的探讨康莱特注射液联合贝伐珠单抗+培美曲塞+顺铂方案治疗晚期肺腺癌的疗效与安全性。
方法选取2016年9月至2019年9月本院收治的92例肺腺癌患者，随机分为研究组（n=47）和对照组（n=45），两组均给予贝伐珠单抗+培美曲塞+顺铂方案治疗，研究组患者在化疗基础上联合康莱特注射液治疗，比较两组患者的疗效、不良反应及生存情况。
结果两组客观有效率、疾病控制率比较差异无统计学意义。
研究组Ⅰ～Ⅲ度白细胞下降、血小板下降及恶心、呕吐的发生率明显低于对照组，差异有统计学意义（P＜0.05）。
研究组血红蛋白减少、转氨酶升高及高血压发生率分别为53.2%，8.5%，21.3%，均为Ⅰ～Ⅱ度，对照组分别为48.9%，15.6%，22.2%，两组比较差异均无统计学意义。
研究组和对照组患者的1年生存率分别为81.9%、72.1%，2年生存率分别为60.4%、56.6%，差异无统计学意义。
结论康莱特注射液联合化疗治疗晚期肺腺癌患者可在一定程度上减少化疗不良反应，提高生活质量。
关键词：康莱特注射液；化疗；疗效；不良反应Kanglaite injection combined with chemotherapy in the treatment of advanced adenocarcinoma of lungZHANG Yurong,SANG Die,FAN Shanmin,ZHAO Xiaohui(Department of Medical Oncology,Beijing Chaoyang District Sanhuan Cancer Hospital,Beijing,100122，China) Abstract:Objective To investigate the efficacy and safety of kanglaite injection combined with bevacizumab+pemetrexed+cisplatin in the treatment of advanced lung adenocarcinoma.Methods92patients with lung adenocarcinoma admitted to our hospital from September2016to Sep-tember2019were selected and randomly divided into study group(n=47)and control group(n=45).Both groups were treated with bevacizumab+ pemetrexed+cisplatin.The study group was treated with kanglaite injection on the basis of chemotherapy.The efficacy,adverse reactions and survival between the two groups were compared.Results There was no significant difference in objective effective rate and disease control rate between the two groups.The incidence of grade I-III leukopenia,thrombocytopenia,nausea and vomiting in the study group were significantly lower than those in the control group(P＜0.05).The incidences of hemoglobin decrease,transaminase increase and hypertension in the study group were53.2%,8.5% and21.3%respectively,which were grade I-II,while those in the control group were48.9%,15.6%and22.2%,respectively.There was no significant difference between the two groups.The1-year survival rates of the study group and the control group were81.9%and72.1%,respectively,and the2-year survival rates were60.4%and56.6%,respectively.Conclusion Kanglaite injection combined with chemotherapy in the treatment of advanced lung adenocarcinoma can certain extent reduce the adverse reactions of chemotherapy and improve the quality of life.Key words:Kanglaite injection;Chemotherapy;Curative effect;Adverse reactions肺癌是全世界发病率和死亡率最高的恶性肿瘤，整体5年生存率约为13%，预后较差[1]。
基于GEO数据库结合网络药理学及分子对接逆向挖掘干预肝癌的中药
基于GEO数据库结合网络药理学及分子对接逆向挖掘干预肝癌的中药魏泽坤;杨雨洁;刘双;王燕;董红敬;刘春梅【期刊名称】《山东科学》【年(卷),期】2024(37)3【摘要】基于GEO(gene expression omnibus)数据库结合网络药理学及分子对接,从分子水平逆向挖掘具有抗肝癌活性的中药。
通过GEO、GeneCards、OMIM 和TTD等疾病靶点数据库获取肝癌的重要靶点。
利用STRING平台获取核心靶点,结合TCMIP(integrative pharmacology-based research platform of traditonal Chinese medicine)和TCMID(traditional Chinese medicine integraive database)数据库筛选核心成分,采用TCMSP(traditonal Chinese medicine system pharmacology database and analysis platform)数据库筛选核心中药,通过分子对接和细胞实验验证筛选结果。
从疾病靶点数据库得到398个肝癌的重要靶点,进一步筛选出8个核心靶点、11个核心成分和1味核心中药葛根;分子对接结果表明葛根的3个核心成分(槲皮素、黄岑素、豆甾醇)可以与部分核心靶点(CDK1、CDC20)自发地结合;细胞实验结果表明葛根提取物可以有效抑制肝癌细胞HepG2的增殖。
该结果可以为葛根的研究与开发提供参考,为葛根抗肝癌活性成分的挖掘提供理论依据。
【总页数】9页(P39-47)【作者】魏泽坤;杨雨洁;刘双;王燕;董红敬;刘春梅【作者单位】山东中医药大学中医学院;山东中医药大学附属医院;齐鲁工业大学(山东省科学院)山东省分析测试中心【正文语种】中文【中图分类】R285【相关文献】1.基于GEO芯片挖掘联合网络药理学分析解毒化瘀颗粒治疗肝癌的分子机制2.基于网络药理学联合GEO数据库及分子对接技术探讨化瘀丸治疗乳腺癌的作用机制3.基于GEO芯片挖掘联合网络药理学及分子对接探讨当归补血汤治疗股骨头坏死分子机制4.基于网络药理学联合GEO数据库及分子对接探究脑安胶囊治疗缺血性脑卒中的作用5.基于网络药理学和分子对接技术结合GEO芯片探究补中清利汤治疗IgA肾病的作用机制因版权原因，仅展示原文概要，查看原文内容请购买。
靶点B-Raf的抑制剂GDC-0834的介绍
GDC-0879是一种新型，有效的，选择性的B-Raf抑制剂，IC50为0.13 nM，对c-Raf也有抑制作用；对其他蛋白激酶没有抑制作用。
体外研究，在V600E B-Raf 突变的A375黑色素瘤和V600E B-Raf突变的Colo205结肠癌细胞系中，GDC-0879抑制MEK1磷酸化作用时IC50分别为59和29 nM。
GDC-0879有效抑制Malme3M细胞的B-raf V600E 酶促作用，IC50为0.75 μM。
用GDC-0879处理，EC50值<0.5的细胞都表达B-raf V600E 致癌等位基因
(A375,624,SK-MEL-28,Malme3M, C32, 928, 888, G-361, Colo205, Colo206, SW1417, CL34,及Colo201)。
体内：GDC-0879处理的鼠细胞系和病患衍生的B-raf V600E肿瘤，显示更强和更持久的药效抑制性(处理8小时，>90%) 且与突变型KRAS-表达的肿瘤相比具有更高的生存力。
Ras诱导肿瘤形成时有激活的Raf信号，但是用GDC-0879处理后，观察到一些KRAS-突变肿瘤的生长进展很慢。
GDC-0879调节的高效性完全与BRAFV600E 的状况有关，抑制MEK减弱表达野生型B-raf肿瘤的生长和增殖。
通过PI3K通路活性的药理学和基因的调节，可以很明显地改变BRAFV600E 黑色素瘤细胞对GDC-0879的反应性。
气相色谱-质谱联用法测定人血浆中双氯芬酸钠的含量的开题报告
气相色谱-质谱联用法测定人血浆中双氯芬酸钠的含量的开题报告一、选题背景及意义双氯芬酸钠是一种常用的非甾体抗炎药物，常用于缓解轻至中度疼痛、发热以及各种炎症所引起的不适。
随着双氯芬酸钠的广泛应用，其药代动力学和药效学研究也变得十分重要。
气相色谱-质谱联用技术（GC-MS）是一种高灵敏度、高分辨率的检测方法，已被广泛用于生物样品中药物含量的定量分析。
因此，利用GC-MS技术对人血浆中双氯芬酸钠的含量进行精准测定，对于深入了解其行为与代谢机制具有重要的意义。
二、文献综述目前已有很多研究使用GC-MS测定双氯芬酸钠在生物样品中的含量。
例如，一项研究使用ODS镀硅烷化液相色谱-质谱联用技术（LC-MS/MS）测定人血浆中双氯芬酸钠的含量，结果表明，该方法具有高灵敏度、高选择性和准确性，可用于临床前药代动力学和生物等效性研究。
但该方法需要较长的分析时间和复杂的操作过程，因此不太适用于临床的快速检测。
相比之下，GC-MS技术具有更快的分析速度和更高的灵敏度，可用于临床的快速检测。
三、研究计划及方法本研究旨在建立一种使用GC-MS测定人血浆中双氯芬酸钠含量的方法，具体步骤如下：1.样品制备：收集20份人血浆样品，加入内标氯苯甲酸钠，经蛋白沉淀、液液萃取等步骤制备样品。
2.峰面积的选择：使用NIST MS搜索库鉴定双氯芬酸钠和氯苯甲酸钠的质谱离子，通过研究不同离子峰的面积发现，以m/z 193和227离子峰进行测定时，信噪比最高。
3.分析条件的优化：选择一系列的分析条件，包括柱温、进样量、进样方式、质谱扫描方式等，对分析条件进行优化。
4.检测方法的验证：测定20个血清样品，进行精密度、准确度、线性范围、检测限和定量限等方面的检测方法验证。
四、预期结果及意义本研究预期建立一种快速、准确、重复性高的GC-MS测定人血浆中双氯芬酸钠的方法。
该方法可用于临床的快速检测，深入了解其药代动力学和药效学研究具有重要意义。